Company Overview and News

4
D-Street Buzz: Nifty auto underperforms as Tata Motors tanks 13%; sugar stocks rally

2018-10-09 moneycontrol
The Indian stock market has once again slipped into the red this Tuesday afternoon with the Nifty50 shedding 13 points, trading at 10,334 while the Sensex has lost over 12 points at 34,462.
MUTHOOTFIN 500325 533150 524816 RELIANCE 538268 533398 BHRQY ABAN 505200 532343 NATCOPHARM RIGD 500850 500570 BHARTIARTL ZEEL 500493 INDHOTEL TATAMOTORS EICHERMOT WONDERLA 503100 BHARATFORG RLNIY YESBANK EXIDEIND ECQRY UBNC TVSMOTOR PHOENIXLTD 511072 532648 YYBKY 532454 DHFL EXQDY GODREJPROP ZEEEY 505537 500086 523204 TTM

 
Nifty likely to remain volatile ahead of expiry; ACC, Bharti Airtel among top shorting ideas

2018-09-25 moneycontrol
The markets continued its decline for the third successive week and lost over 3 percent. Weak domestic cues and not so supportive global markets pushed the bulls completely on the back foot.
532454 EXIDEIND EXQDY 500086 BHRQY BHARTIARTL

 
D-Street Buzz: Over 300 stocks hit fresh 52-week low on NSE; IT gains with Infibeam up 11%, realty stocks bleed

2018-09-24 moneycontrol
It is Monday mayhem on Dalal Street which is witnessing continued bloodbath as the Indian stock market is down 1.5 percent. The Nifty50 is down over 170 points and is trading below the 11,ooo mark while the Sensex is trading lower by 500 points at 36,328.
SWANENERGY TCHQY 532834 532832 532755 535789 532480 CAMLINFIN EICHERMOT CLNDY ASHOKLEY EXIDEIND RELCAPITAL 511072 ALBK JETAIRWAYS YYBKY 517334 AKLD 531213 TECHM DHFL EXQDY TCS COALINDIA AKLS IBREALEST 533271 533150 532617 533273 ASHOKA DELTAMAGNT TTNQY 533278 505200 MOZTY 532540 532187 MANAPPURAM 500477 503100 500111 YESBANK ECQRY PHOENIXLTD INDUSINDBK IDKQY 532648 504286 IBULHSGFIN OBZIY GODREJPROP OBEROIRLTY MOTHERSUMI 500086 503310

 
Websol Energy Systems Limited

2018-09-06 thehindubusinessline
Websol Energy Systems has entered into a production agreement with Exide Industries. Accordingly, Websol will manufacture and supply 10-MW of Photo Voltaic Modules per month comprising 40 MW, to EIL, under the Exide brand at its factory at Falta SEZ. The agreement is valid till December 31, 2018 and may be renewed on mutually agreed terms and conditions. Shares of Websol Energy jumped 4.97 per cent at ₹42.
EXIDEIND EXQDY 500086

 
D-Street Buzz: IT, pharma stocks rise led by Wipro, Dr Reddy#39;s Labs; Network18 zooms 15%

2018-09-03 moneycontrol
The Indian market is trading on a handsome note this Monday morning with the Nifty50 up 32 points at 11,712 while the Sensex is trading higher by 124 points at 38,769.
EKC BAJAJ-AUTO TCHQY 532977 532755 CADILAHC 505200 532321 532684 500477 500493 EICHERMOT BHARATFORG ASHOKLEY EXIDEIND ECQRY 517354 HINDALCO HVLQY ALBERTDA AKLD CDLYY TECHM HNDNF EXQDY 524075 GAMMONIND HAVELLS 509550 GOODRICKE 500086 AKLS 500440 500166

 
Exide Industries Limited - Updates

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
EXIDEIND EXQDY 500086

 
D-Street Buzz: Metals shine led by Hindustan Zinc, JSW Steel; Pfizer zooms 12%, hits fresh 52-week high

2018-08-24 moneycontrol
The Indian market continues to trade in the red this Friday afternoon with the Nifty down 24 points and trading at 11,558. The Sensex on the other hand is trading lower by 79 points and is trading at 38,257.
AMKD 500325 UBL 532715 532478 CADILAHC 532321 532483 KSCL BJJQY RLNIY EXIDEIND AXB YYBKY JSWSTEEL CNRYY AXBA EXQDY BAJFINANCE BATAINDIA CANBK 507458 500188 HINDZINC 500228 RELIANCE AMTEKAUTO HNDZY 532899 532215 GITANJALI AXISBANK RIGD 500034 YESBANK UBNC IBN UBHOLDINGS 532648 UNBWY CDLYY 539207 AXBKY GTJLY ICICIBANK 532174 520077 500086 500043 MANPASAND

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...